Growth differentiation factor-15 may be a novel biomarker in pancreatic cancer: A review

Meng Guo,Hui Zhao

DOI: https://doi.org/10.1097/md.0000000000036594

IF: 1.6

2024-02-10

Medicine

Abstract:Due to the lack of typical symptoms and signs in the early stages, as well as its aggressive nature and high malignancy, pancreatic cancer often has a grim prognosis and high mortality rate. It is projected to become the second leading cause of cancer-related deaths by 2030. [ 1 , 2 ] Surgical resection is the most effective method for treating patients with pancreatic cancer at present. However, only a small percentage (15%–20%) of newly diagnosed patients are eligible for surgery. In comparison, the majority (80%) are diagnosed with either locally advanced or metastatic pancreatic cancer, rendering them ineligible for surgery. These patients often have to resort to palliative treatments such as chemotherapy, radiotherapy, and immunotherapy. Unfortunately, the results and prognosis of these treatments are not favorable. Therefore, early detection and treatment are crucial for improving outcomes in pancreatic cancer patients. [ 3 , 4 ] Due to its universality and rapid imaging characteristics,CT is the first choice for evaluating patients with suspicious conditions. However, CT has a low detection rate for isodense lesions and small masses. On the other hand, MRI has better resolution compared to CT. Nevertheless, MRI has some disadvantages, such as the absence of standardized parameters for advanced imaging sequences, limited spatial resolution, susceptibility to patient movement and intestinal gas, and challenges for patients with claustrophobia. [ 5 , 6 ] Endoscopic ultrasound has better sensitivity and specificity for detecting pancreatic cancer, and it is more accurate in detecting small lesions (0.5–2 cm). [ 7 ] However, experiments conducted on animal models have shown that changes in molecular markers occur before structural changes are detected by imaging techniques in the pancreas. As a result, more studies have begun to focus on identifying molecular markers. [ 8 ]

medicine, general & internal